The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Postmenopausal Vaginal Atrophy Therapeutics Market Research Report 2025

Global Postmenopausal Vaginal Atrophy Therapeutics Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1685538

No of Pages : 89

Ask Your Query

Synopsis

Postmenopausal vaginal atrophy (PVA), also referred to as postmenopausal atrophic vaginitis, caused by the vaginal walls' drying, thinning, and inflammation due to reduced estrogen levels. Women with this disorder are more vulnerable to problems of urinary system and chronic infection of vaginal linings. A variety of medications and therapies available in market that focuses on the underlying cause as well as the symptoms of the condition. These therapies also helps women to improve their quality of life.

Global Postmenopausal Vaginal Atrophy Therapeutics market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Postmenopausal Vaginal Atrophy Therapeutics market research.

Key companies engaged in the Postmenopausal Vaginal Atrophy Therapeutics industry include Endoceutics, Accord Healthcare, Pfizer, Novo Nordisk, Teva Pharmaceuticals, Shionogi, Bionovo, QuatRx Pharmaceutical Company and Bayer AG, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.

When refers to consumption region, % value of Postmenopausal Vaginal Atrophy Therapeutics were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Postmenopausal Vaginal Atrophy Therapeutics market and estimated to attract more attentions from industry insiders and investors.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Postmenopausal Vaginal Atrophy Therapeutics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company

  •     Endoceutics
  •     Accord Healthcare
  •     Pfizer
  •     Novo Nordisk
  •     Teva Pharmaceuticals
  •     Shionogi
  •     Bionovo
  •     QuatRx Pharmaceutical Company
  •     Bayer AG
  •     TherapeuticsMD

Segment by Type

  •     Estrogen-based Drugs
  •     Non-estrogen-based Drugs

Segment by Application

  •     Hospital
  •     Specialist Clinic

By Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia, Nordic Countries, Rest of Europe)
  • Asia-Pacific (China, Japan, South Korea,Southeast Asia, India, Australia, Rest of Asia)
  • Latin America (Mexico, Brazil, Rest of Latin America)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)

The Postmenopausal Vaginal Atrophy Therapeutics report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source

Index

 

1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Postmenopausal Vaginal Atrophy Therapeutics Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
        1.2.2 Estrogen-based Drugs
        1.2.3 Non-estrogen-based Drugs
    1.3 Market by Application
        1.3.1 Global Postmenopausal Vaginal Atrophy Therapeutics Market Growth by Application: 2018 VS 2022 VS 2029
        1.3.2 Hospital
        1.3.3 Specialist Clinic
    1.4 Study Objectives
    1.5 Years Considered
    1.6 Years Considered

 2 Global Growth Trends
    2.1 Global Postmenopausal Vaginal Atrophy Therapeutics Market Perspective (2018-2029)
    2.2 Postmenopausal Vaginal Atrophy Therapeutics Growth Trends by Region
        2.2.1 Global Postmenopausal Vaginal Atrophy Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
        2.2.2 Postmenopausal Vaginal Atrophy Therapeutics Historic Market Size by Region (2018-2023)
        2.2.3 Postmenopausal Vaginal Atrophy Therapeutics Forecasted Market Size by Region (2024-2029)
    2.3 Postmenopausal Vaginal Atrophy Therapeutics Market Dynamics
        2.3.1 Postmenopausal Vaginal Atrophy Therapeutics Industry Trends
        2.3.2 Postmenopausal Vaginal Atrophy Therapeutics Market Drivers
        2.3.3 Postmenopausal Vaginal Atrophy Therapeutics Market Challenges
        2.3.4 Postmenopausal Vaginal Atrophy Therapeutics Market Restraints

 3 Competition Landscape by Key Players
    3.1 Global Top Postmenopausal Vaginal Atrophy Therapeutics Players by Revenue
        3.1.1 Global Top Postmenopausal Vaginal Atrophy Therapeutics Players by Revenue (2018-2023)
        3.1.2 Global Postmenopausal Vaginal Atrophy Therapeutics Revenue Market Share by Players (2018-2023)
    3.2 Global Postmenopausal Vaginal Atrophy Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Postmenopausal Vaginal Atrophy Therapeutics Revenue
    3.4 Global Postmenopausal Vaginal Atrophy Therapeutics Market Concentration Ratio
        3.4.1 Global Postmenopausal Vaginal Atrophy Therapeutics Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Postmenopausal Vaginal Atrophy Therapeutics Revenue in 2022
    3.5 Postmenopausal Vaginal Atrophy Therapeutics Key Players Head office and Area Served
    3.6 Key Players Postmenopausal Vaginal Atrophy Therapeutics Product Solution and Service
    3.7 Date of Enter into Postmenopausal Vaginal Atrophy Therapeutics Market
    3.8 Mergers & Acquisitions, Expansion Plans

 4 Postmenopausal Vaginal Atrophy Therapeutics Breakdown Data by Type
    4.1 Global Postmenopausal Vaginal Atrophy Therapeutics Historic Market Size by Type (2018-2023)
    4.2 Global Postmenopausal Vaginal Atrophy Therapeutics Forecasted Market Size by Type (2024-2029)

 5 Postmenopausal Vaginal Atrophy Therapeutics Breakdown Data by Application
    5.1 Global Postmenopausal Vaginal Atrophy Therapeutics Historic Market Size by Application (2018-2023)
    5.2 Global Postmenopausal Vaginal Atrophy Therapeutics Forecasted Market Size by Application (2024-2029)

 6 North America
    6.1 North America Postmenopausal Vaginal Atrophy Therapeutics Market Size (2018-2029)
    6.2 North America Postmenopausal Vaginal Atrophy Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
    6.3 North America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country (2018-2023)
    6.4 North America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country (2024-2029)
    6.5 United States
    6.6 Canada

 7 Europe
    7.1 Europe Postmenopausal Vaginal Atrophy Therapeutics Market Size (2018-2029)
    7.2 Europe Postmenopausal Vaginal Atrophy Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
    7.3 Europe Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country (2018-2023)
    7.4 Europe Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country (2024-2029)
    7.5 Germany
    7.6 France
    7.7 U.K.
    7.8 Italy
    7.9 Russia
    7.10 Nordic Countries

 8 Asia-Pacific
    8.1 Asia-Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Size (2018-2029)
    8.2 Asia-Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Growth Rate by Region: 2018 VS 2022 VS 2029
    8.3 Asia-Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Size by Region (2018-2023)
    8.4 Asia-Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Size by Region (2024-2029)
    8.5 China
    8.6 Japan
    8.7 South Korea
    8.8 Southeast Asia
    8.9 India
    8.10 Australia

 9 Latin America
    9.1 Latin America Postmenopausal Vaginal Atrophy Therapeutics Market Size (2018-2029)
    9.2 Latin America Postmenopausal Vaginal Atrophy Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
    9.3 Latin America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country (2018-2023)
    9.4 Latin America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country (2024-2029)
    9.5 Mexico
    9.6 Brazil

 10 Middle East & Africa
    10.1 Middle East & Africa Postmenopausal Vaginal Atrophy Therapeutics Market Size (2018-2029)
    10.2 Middle East & Africa Postmenopausal Vaginal Atrophy Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
    10.3 Middle East & Africa Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country (2018-2023)
    10.4 Middle East & Africa Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country (2024-2029)
    10.5 Turkey
    10.6 Saudi Arabia
    10.7 UAE

 11 Key Players Profiles
    11.1 Endoceutics
        11.1.1 Endoceutics Company Detail
        11.1.2 Endoceutics Business Overview
        11.1.3 Endoceutics Postmenopausal Vaginal Atrophy Therapeutics Introduction
        11.1.4 Endoceutics Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2018-2023)
        11.1.5 Endoceutics Recent Development
    11.2 Accord Healthcare
        11.2.1 Accord Healthcare Company Detail
        11.2.2 Accord Healthcare Business Overview
        11.2.3 Accord Healthcare Postmenopausal Vaginal Atrophy Therapeutics Introduction
        11.2.4 Accord Healthcare Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2018-2023)
        11.2.5 Accord Healthcare Recent Development
    11.3 Pfizer
        11.3.1 Pfizer Company Detail
        11.3.2 Pfizer Business Overview
        11.3.3 Pfizer Postmenopausal Vaginal Atrophy Therapeutics Introduction
        11.3.4 Pfizer Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2018-2023)
        11.3.5 Pfizer Recent Development
    11.4 Novo Nordisk
        11.4.1 Novo Nordisk Company Detail
        11.4.2 Novo Nordisk Business Overview
        11.4.3 Novo Nordisk Postmenopausal Vaginal Atrophy Therapeutics Introduction
        11.4.4 Novo Nordisk Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2018-2023)
        11.4.5 Novo Nordisk Recent Development
    11.5 Teva Pharmaceuticals
        11.5.1 Teva Pharmaceuticals Company Detail
        11.5.2 Teva Pharmaceuticals Business Overview
        11.5.3 Teva Pharmaceuticals Postmenopausal Vaginal Atrophy Therapeutics Introduction
        11.5.4 Teva Pharmaceuticals Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2018-2023)
        11.5.5 Teva Pharmaceuticals Recent Development
    11.6 Shionogi
        11.6.1 Shionogi Company Detail
        11.6.2 Shionogi Business Overview
        11.6.3 Shionogi Postmenopausal Vaginal Atrophy Therapeutics Introduction
        11.6.4 Shionogi Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2018-2023)
        11.6.5 Shionogi Recent Development
    11.7 Bionovo
        11.7.1 Bionovo Company Detail
        11.7.2 Bionovo Business Overview
        11.7.3 Bionovo Postmenopausal Vaginal Atrophy Therapeutics Introduction
        11.7.4 Bionovo Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2018-2023)
        11.7.5 Bionovo Recent Development
    11.8 QuatRx Pharmaceutical Company
        11.8.1 QuatRx Pharmaceutical Company Company Detail
        11.8.2 QuatRx Pharmaceutical Company Business Overview
        11.8.3 QuatRx Pharmaceutical Company Postmenopausal Vaginal Atrophy Therapeutics Introduction
        11.8.4 QuatRx Pharmaceutical Company Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2018-2023)
        11.8.5 QuatRx Pharmaceutical Company Recent Development
    11.9 Bayer AG
        11.9.1 Bayer AG Company Detail
        11.9.2 Bayer AG Business Overview
        11.9.3 Bayer AG Postmenopausal Vaginal Atrophy Therapeutics Introduction
        11.9.4 Bayer AG Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2018-2023)
        11.9.5 Bayer AG Recent Development
    11.10 TherapeuticsMD
        11.10.1 TherapeuticsMD Company Detail
        11.10.2 TherapeuticsMD Business Overview
        11.10.3 TherapeuticsMD Postmenopausal Vaginal Atrophy Therapeutics Introduction
        11.10.4 TherapeuticsMD Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2018-2023)
        11.10.5 TherapeuticsMD Recent Development

 12 Analyst's Viewpoints/Conclusions

 13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock